William R Usinger from Volcano, CA, age 74

Us Patents

Connective Tissue Growth Factor Antibodies
view source
US Patent:

7405274, Jul 29, 2008
Filed:

Jun 1, 2004
Appl. No.:

10/858186
Inventors:

Al Y. Lin - Castro Valley CA, US
Thomas B. Neff - Atherton CA, US
Noelynn A. Oliver - Los Altos CA, US
William R. Usinger - Lafayette CA, US
Qingjian Wang - Belmont CA, US
David A. Yeowell - San Francisco CA, US
Assignee:

FibroGen, Inc. - South San Francisco CA
International Classification:

C12P 21/08
C07K 16/00
US Classification:

5303871, 5303873, 5303881, 53038823
Abstract:

The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.

Antibodies That Bind To A Portion Of The Vwc Domain Of Connective Tissue Growth Factor
view source
US Patent:

7871617, Jan 18, 2011
Filed:

Jun 9, 2008
Appl. No.:

12/157262
Inventors:

Al Y. Lin - Castro Valley CA, US
Thomas B. Neff - Atherton CA, US
Noelynn A. Oliver - Los Altos CA, US
William R. Usinger - Lafayette CA, US
Qingjian Wang - Belmont CA, US
David A. Yeowell - San Francisco CA, US
Assignee:

FibroGen, Inc. - San Francisco CA
International Classification:

A61K 39/395
A61K 38/18
US Classification:

4241391, 4241411, 4241451, 4241581, 4241331, 5303873, 5303879, 5303881, 53038824, 530399
Abstract:

The present invention relates to antibodies that bind to a portion of the Von Willebrand's factor (VWC) domain of connective tissue growth factor (CTGF). The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.

Diabetic Nephropathy Therapies
view source
US Patent:

8314059, Nov 20, 2012
Filed:

Jun 3, 2010
Appl. No.:

12/802373
Inventors:

Allan Flyvbjerg - Odder, DK
Guangjie Guo - Foster City CA, US
David Y. Liu - Palo Alto CA, US
Thomas B. Neff - Atherton CA, US
Noelynn A. Oliver - Los Altos CA, US
William R. Usinger - Lafayette CA, US
Qingjian Wang - Foster City CA, US
Assignee:

FibroGen, Inc. - San Francisco CA
International Classification:

A61K 38/00
A61K 38/17
US Classification:

514 11, 514 2192
Abstract:

The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided.

Diabetic Nephropathy Therapies
view source
US Patent:

20050214294, Sep 29, 2005
Filed:

Feb 11, 2005
Appl. No.:

11/057323
Inventors:

Allan Flyvbjerg - Asylgade, DK
Guangjie Guo - Foster City CA, US
David Liu - Palo Alto CA, US
Thomas Neff - Atherton CA, US
Noelynn Oliver - Los Altos CA, US
William Usinger - Lafayette CA, US
Qingjian Wang - Belmont CA, US
International Classification:

A61K039/395
US Classification:

424145100
Abstract:

The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided.

Diagnostic Marker For Diabetic Vascular Complications
view source
US Patent:

20090325302, Dec 31, 2009
Filed:

May 5, 2006
Appl. No.:

11/919607
Inventors:

Ayad A. Jaffa - Mount Pleasant SC, US
William R. Usinger - Lafayette CA, US
Assignee:

FibroGen, Inc. - South San Francisco CA
International Classification:

G01N 33/68
US Classification:

436 86
Abstract:

The present invention relates to the discovery that CTGF is a diagnostic marker indicative of increased risk for development and progression of vascular disease.

Connective Tissue Growth Factor Antibodies
view source
US Patent:

20110091468, Apr 21, 2011
Filed:

Nov 10, 2010
Appl. No.:

12/927243
Inventors:

Al Y. Lin - Castro Valley CA, US
Thomas B. Neff - Atherton CA, US
Noelynn A. Oliver - Los Altos CA, US
William R. Usinger - Lafayette CA, US
Qingjian Wang - Belmont CA, US
David A. Yeowell - San Francisco CA, US
Assignee:

FibroGen, Inc. - San Francisco CA
International Classification:

A61K 39/395
C07K 16/22
A61P 3/10
A61P 35/04
A61P 9/00
A61P 19/02
A61P 9/12
US Classification:

4241391, 5303879
Abstract:

The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.

Antibodies Useful In Passive Influenza Immunization
view source
US Patent:

20120020971, Jan 26, 2012
Filed:

Jun 17, 2011
Appl. No.:

13/163489
Inventors:

Lawrence M. KAUVAR - San Francisco CA, US
Stote Ellsworth - Palo Alto CA, US
William Usinger - Lafayette CA, US
Krista M. McCutcheon - Burlingame CA, US
Minha Park - Brisbane CA, US
Bo Chen - Daly City CA, US
Ying-Ping Jiang - Lafayette CA, US
Assignee:

Trellis Bioscience, Inc. - South San Francisco CA
International Classification:

A61K 39/42
A61P 31/00
C12N 5/10
C12N 15/85
C12P 21/08
C07K 16/10
A61P 31/16
US Classification:

4241361, 5303883, 5303873, 53038815, 4241471, 4353201, 435 696, 435366
Abstract:

Monoclonal antibodies and fragments thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.

High Affinity Human Antibodies To Human Cytomegalovirus (Cmv) Gb Protein
view source
US Patent:

20120020980, Jan 26, 2012
Filed:

Jun 16, 2011
Appl. No.:

13/162497
Inventors:

LAWRENCE M. KAUVAR - SAN FRANCISCO CA, US
STOTE ELLSWORTH - PALO ALTO CA, US
WILLIAM USINGER - LAFAYETTE CA, US
KRISTA MAUREEN MCCUTCHEON - BURLINGAME CA, US
YING-PING JIANG - LAFAYETTE CA, US
FEN ZHANG - SAN FRANCISCO CA, US
BO CHEN - DALY CITY CA, US
GIZETTE SPERINDE - SAN FRANCISCO CA, US
MINHA PARK - BRISBANE CA, US
ORIT FOORD - FOSTER CITY CA, US
Assignee:

TRELLIS BIOSCIENCE, INC. - SOUTH SAN FRANCISCO CA
International Classification:

A61K 39/42
C12N 5/10
A61P 31/20
C12P 21/08
C07K 16/08
C12N 15/13
C12N 1/00
US Classification:

4241421, 536 2353, 435339, 435243, 435419, 435 696, 53038815, 5303873
Abstract:

Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.

Name / Title

Company / Classification

Phones & Addresses

William Robert Usinger
President

IMMUSINE INC

*North Ln, Orinda, CA 94563

William Robert Usinger
President

COMPLIMMUNE INCORPORATED

25 N Ln, Orinda, CA 94563

William R. Usinger
President

HOMECARE TECHNOLOGIES, INC

2407 Dowling Pl #4, Berkeley, CA 94705

Resumes

Vice President, Head Of R&D At Trellis Bioscience

view source

Location:

San Francisco Bay Area

Industry:

Biotechnology

Experience:

Trellis Bioscience (Privately Held; Biotechnology industry): Vice President, Head of R&D, (2010-Present) Novartis (Biotechnology industry): Director Research, (2005-2009) Led multi-discipline effort to identify and characterize monoclonal antibody ...